FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Ascension Health   2. Issuer Name and Ticker or Trading Symbol Accretive Health, Inc. [AH] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 4600 EDMUNDSON ROAD 3. Date of Earliest Transaction (Month/Day/Year) 05/19/2010 (Street) ST. LOUIS, MO 63134 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 05/19/2010   X   874,532 (1) A $ 4.43 (1) 8,326,385 D   Common Stock 05/19/2010   J   322,744 (1) D $ 12 (1) 8,003,641 D   Common Stock 05/19/2010   X   437,268 (2) A $ 10.25 (2) 8,440,909 D   Common Stock 05/19/2010   J   373,407 (2) D $ 12 (2) 8,067,502 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Warrant (Right to Buy)

$ 4.43 (1)

05/19/2010

X(1)

874,532

(3)

(4)

Common Stock

874,532

$ 0

0

D

Warrant (Right to Buy)

$ 10.25 (2)

05/19/2010

X(2)

437,268

(5)

(4)

Common Stock

437,268

$ 0

0

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Ascension Health 4600 EDMUNDSON ROAD ST. LOUIS, MO 63134		X

Signatures

/s/ Anthony J. Speranzo		05/21/2010
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The Reporting Person exercised this warrant on a cashless basis, simultaneous with the execution and delivery of the underwriting agreement related to the Issuer's initial public offering, based on the initial public offering price per share of $12.00, resulting in the issuance to the Reporting Person of 551,788 shares of Common Stock and cancellation of the warrant with respect to the balance of 322,744 shares of Common Stock.
(2)	The Reporting Person exercised this warrant on a cashless basis, simultaneous with the execution and delivery of the underwriting agreement related to the Issuer's initial public offering, based on the initial public offering price per share of $12.00, resulting in the issuance to the Reporting Person of 63,861 shares of Common Stock and cancellation of the warrant with respect to the balance of 373,407 shares of Common Stock.
(3)	The warrants to purchase 874,532 shares of Common Stock with an exercise price of $4.43 per share were immediately exercisable when issued in December 2007.
(4)	The warrants expire upon the effective date of the Issuer's initial public offering.
(5)	The warrants to purchase 437,268 shares of Common Stock with an exercise price of $10.25 per share were immediately exercisable when issued in March 2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.